SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

25.55 11.33

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

25.25

Max

25.6

Põhinäitajad
By Trading Economics
Sissetulek	-5.4M
Müük	27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	1.1M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	-10.85% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	1. apr 2026

Turustatistika
By TradingEconomics
Turukapital	1B
Eelmine avamishind	14.22
Eelmine sulgemishind	25.55

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. märts 2026, 23:35 UTC

Uudisväärsed sündmused

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

1. märts 2026, 23:49 UTC

Market Talk

Uudisväärsed sündmused

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

1. märts 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

1. märts 2026, 23:41 UTC

Market Talk

Uudisväärsed sündmused

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

1. märts 2026, 23:39 UTC

Market Talk

Uudisväärsed sündmused

Global Equities Roundup: Market Talk

1. märts 2026, 23:39 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

1. märts 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

1. märts 2026, 23:24 UTC

Market Talk

Global Energy Roundup: Market Talk

1. märts 2026, 23:24 UTC

Market Talk

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

1. märts 2026, 23:21 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. märts 2026, 23:21 UTC

Market Talk

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

1. märts 2026, 23:19 UTC

Uudisväärsed sündmused

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

1. märts 2026, 23:17 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

1. märts 2026, 23:14 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

1. märts 2026, 22:55 UTC

Uudisväärsed sündmused

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

1. märts 2026, 22:54 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

1. märts 2026, 22:53 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

1. märts 2026, 22:38 UTC

Market Talk

Uudisväärsed sündmused

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

1. märts 2026, 22:21 UTC

Tulu

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

1. märts 2026, 22:17 UTC

Market Talk

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

1. märts 2026, 22:13 UTC

Market Talk

Uudisväärsed sündmused

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

1. märts 2026, 22:00 UTC

Market Talk

Uudisväärsed sündmused

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

1. märts 2026, 21:40 UTC

Market Talk

Uudisväärsed sündmused

Spot Gold Up as Investors Shield Against Risk -- Market Talk

1. märts 2026, 21:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

1. märts 2026, 21:30 UTC

Market Talk

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

1. märts 2026, 21:27 UTC

Market Talk

Uudisväärsed sündmused

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

1. märts 2026, 21:19 UTC

Market Talk

Uudisväärsed sündmused

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

1. märts 2026, 20:58 UTC

Market Talk

Uudisväärsed sündmused

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

1. märts 2026, 20:40 UTC

Market Talk

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

1. märts 2026, 20:24 UTC

Market Talk

Uudisväärsed sündmused

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

-10.85% langus

12 kuu keskmine prognoos

Keskmine 23 EUR -10.85%

Kõrge 23 EUR

Madal 23 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.